Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Total cash & short-term investments

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndTotal cash & short-term investments (Million USD)YoY (%)
Dec 31, 2024116-2.13%
Dec 31, 2023118-67.42%
Dec 31, 2022363-51.00%
Dec 31, 2021741+101.19%
Dec 31, 2020369-49.02%
Dec 31, 2019723+103.60%
Dec 31, 2018355-24.42%
Dec 31, 2017470+129.15%
Dec 31, 2016205+89.20%
Dec 31, 2015108-20.12%
Dec 31, 2014136+89.67%
Dec 31, 201372-28.43%
Dec 31, 2012100+89.12%
Dec 31, 201153

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat